Program
garetatug rezetecan
Also written as “SHR-A1904”, “SHR-A1904 for Injection” and “SHR-A1904; Adebrelimab”.
In Jiangsu HengRui Medicine’s pipeline, Claudin 18.2 ADC
. Its studies are mostly in Biliary Tract Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Oct 17, 20247 company-led studies, 6 open or runningNext primary completion: Sep 20, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 76 open or running | phase 3since Oct 17, 2024 | Apr 27, 2021 | Sep 20, 2027phase 3 · NCT06649292 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-A1904
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 27, 2021First study: phase 1 study in Advanced Solid CancerFirst studyNCT04877717 · 107 enrolled · China
- Jun 2, 2021Phase 1 study in Advanced Pancreatic CancerNCT04928625 · 75 enrolled · China
- Mar 3, 2022Phase 2 study in Advanced Solid TumorsNCT05277168 · 83 planned · United States, Australia, Moldova and more
- Apr 1, 2024Phase 1 study in CLDN18.2-positive Advanced Solid TumorNCT06350006 · 924 planned · China
- Oct 17, 2024Phase 3 study in Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06649292 · 524 planned · China
- Jul 31, 2025Phase 2 study in Stomach NeoplasmsNCT07110571 · 200 planned · China
- Feb 27, 2026Phase 2 study in Biliary Tract NeoplasmsNCT07450976 · 151 planned · China
Ahead
- Sep 20, 2027Primary completion: phase 3 study in Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06649292
- Dec 30, 2027Primary completion: phase 1 study in CLDN18.2-positive Advanced Solid TumorNCT06350006
- Dec 2030Primary completion: phase 2 study in Biliary Tract NeoplasmsNCT07450976
TargetBeta
“Claudin 18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of garetatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated, via a cleavable linker, to rezetecan, an exatecan derivative and topoisomerase …”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of garetatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07450976Biliary Tract Neoplasms · China | 2 | Recruiting | Dec 2030 | 151 |
| NCT07110571Stomach Neoplasms · China | 2 | Recruiting | Aug 2026 | 200 |
| NCT06649292Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Sep 20, 2027 | 524 |
| NCT06350006CLDN18.2-positive Advanced Solid Tumor · China | 1 | Recruiting | Dec 30, 2027 | 924 |
| NCT05277168Advanced Solid Tumors · United States, Australia, Moldova and more | 2 | Recruiting | May 2026 | 83 |
| NCT04928625Advanced Pancreatic Cancer · China | 1 | UNKNOWN | Jun 30, 2023 | 75 |
| NCT04877717Advanced Solid Cancer · China | 1 | Active, not recruiting | Dec 1, 2025 | 107 |
How it is read
Names in the registry
- “SHR-A1904”, 4 entries
- “SHR-A1904 for Injection”, 2 entries
- “SHR-A1904; Adebrelimab”, 1 entry
- “SHR-A1904; CAPOX; Adebrelimab”, 1 entry
Conditions, from the studies’ own filings
- Biliary Tract Neoplasms, 1 study
- Stomach Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.